StepPharma

StepPharma is a clinical-stage biotechnology company focused on developing a new class of oral drugs that selectively target the enzyme cytidine triphosphate synthase 1 (CTPS1). By inhibiting CTPS1, the company aims to treat a range of hematological malignancies and solid tumors by disrupting the de novo pyrimidine synthesis pathway essential for rapidly proliferating cancer cells. Their lead candidate, STP938, is currently being evaluated in Phase 1/2 clinical trials for patients with relapsed or refractory B-cell and T-cell lymphomas. The company's approach leverages the genetic discovery that CTPS1 is critical for lymphocyte proliferation, offering a potentially more targeted and less toxic alternative to traditional chemotherapies.